Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial

Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial

Background: Precision cancer medicine (PCM) is key to advancing cancer treatment beyond the standard of care. We performed an explorative clinical trial, MEGALiT, to investigate the feasibility, safety, and clinical benefit of genomics-based PCM in advanced cancer. Methods: MEGALiT recruited adult...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lars Ny, Henrik Fagman, Johan Botling, Loviisa Mantovaara, Peter Asplund, Hannah Karlsson, Jennie Aust, Edvard Abel, Mats Hellström, Joakim Crona, Peter Nygren
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2025-06-01
Series:	Acta Oncologica
Subjects:	precision cancer medicine genomics clinical trial targeted drug PD-1/PD-L1inhibitors
Online Access:	https://medicaljournalssweden.se/actaoncologica/article/view/43366
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation
by: Ling Wang, et al.
Published: (2025-06-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
by: Camil Ciprian Mireștean, et al.
Published: (2025-04-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer
by: Yang Zhang, et al.
Published: (2025-05-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

The immune exhaustion paradox: activated functionality during chronic bacterial infections
by: María L Ruiz-de la Cruz, et al.
Published: (2024-12-01)

Immunotherapy as an Innovative Treatment for Non-Small Cell Lung Cancer – A Comprehensive Literature Review
by: Aneta Rasińska, et al.
Published: (2025-05-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical evolution of patients with head and neck cutaneous squamous cell carcinoma?
by: Gustavo Nunes Bento, et al.
Published: (2025-09-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
by: Barry D. Hock, et al.
Published: (2025-05-01)

Clinical characteristics, outcomes, and predictive modeling of patients diagnosed with immune checkpoint inhibitor therapy-related pneumonitis
by: Antonious Hazim, et al.
Published: (2025-05-01)

Serum soluble PD‐1 plays a role in predicting infection complications in patients with acute pancreatitis
by: Xingxing Yu, et al.
Published: (2021-03-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
by: Przemysław Bielski, et al.
Published: (2025-05-01)

Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis
by: Peijun Tang, et al.
Published: (2024-09-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

T-cell invigoration to cell-free DNA ratio associated with anti-PD-1 response in gastric or gastro-esophageal junction adenocarcinoma: VOYAGER trial
by: A. Makiyama, et al.
Published: (2025-06-01)

The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis
by: Deping Luo, et al.
Published: (2025-03-01)

Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: a retrospective study
by: Wentong Liu, et al.
Published: (2025-08-01)

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions
by: Yujin Song, et al.
Published: (2025-08-01)

Theoretical investigation on PD-L1-In-1 for cancer immunotherapy via density functional theory
by: Bijay Sijapati Magar, et al.
Published: (2025-08-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells
by: Fangxin Zhao, et al.
Published: (2025-04-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients
by: Ugur Calis, et al.
Published: (2025-01-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Spatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma
by: Mei-yao He, et al.
Published: (2025-05-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-06-01)

PD-1 agonist: A novel therapeutic approach to resolve atherosclerosis
by: Jiahui Chen, et al.
Published: (2024-12-01)